Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Science Careers Booklet

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 20 November 1987:
Vol. 238. no. 4830, pp. 1098 - 1104
DOI: 10.1126/science.3317828
Prev | Table of Contents | Next

Articles

Science, Vol 238, Issue 4830, 1098-1104
Copyright © 1987 by American Association for the Advancement of Science

articles

Redesigning nature's poisons to create anti-tumor reagents

ES Vitetta, RJ Fulton, RD May, M Till, and JW Uhr

Department of Microbiology, University of Texas Southwestern Medical Center, Dallas 75235.

Immunotoxins are conjugates of cell-reactive antibodies and toxins or their subunits. In this report, the chemistry, biology, pharmacokinetics, and anti-tumor effects of first generation immunotoxins; the preparation of improved second generation immunotoxins that display greater anti-tumor efficacy; and the role of genetic engineering in creating third-generation immunotoxins are discussed.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates.
R. M. Sharkey and D. M. Goldenberg (2006)
CA Cancer J Clin 56, 226-243
   Abstract »    Full Text »    PDF »
Generation of a Complement-Independent Bactericidal IgM against a Relapsing Fever Borrelia.
S. E. Connolly, D. G. Thanassi, and J. L. Benach (2004)
J. Immunol. 172, 1191-1197
   Abstract »    Full Text »    PDF »
Antitumor Activity of SS(dsFv)PE38 and SS1(dsFv)PE38, Recombinant Antimesothelin Immunotoxins against Human Gynecologic Cancers Grown in Organotypic Culture in Vitro.
R. Hassan, M. R. Lerner, D. Benbrook, S. A. Lightfoot, D. J. Brackett, Q.-C. Wang, and I. Pastan (2002)
Clin. Cancer Res. 8, 3520-3526
   Abstract »    Full Text »    PDF »
Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
P. Borchmann, R. Schnell, I. Fuss, O. Manzke, T. Davis, L. D. Lewis, D. Behnke, C. Wickenhauser, P. Schiller, V. Diehl, et al. (2002)
Blood 100, 3101-3107
   Abstract »    Full Text »    PDF »
Design of protein struts for self-assembling nanoconstructs.
P. Hyman, R. Valluzzi, and E. Goldberg (2002)
PNAS 99, 8488-8493
   Abstract »    Full Text »    PDF »
High Affinity Restricts the Localization and Tumor Penetration of Single-Chain Fv Antibody Molecules.
G. P. Adams, R. Schier, A. M. McCall, H. H. Simmons, E. M. Horak, R. K. Alpaugh, J. D. Marks, and L. M. Weiner (2001)
Cancer Res. 61, 4750-4755
   Abstract »    Full Text »    PDF »
In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate.
Y. SATO, N. YAMAUCHI, M. TAKAHASHI, K. SASAKI, J. FUKAURA, H. NEDA, S. FUJII, M. HIRAYAMA, Y. ITOH, Y. KOSHITA, et al. (2000)
FASEB J 14, 2108-2118
   Abstract »    Full Text »
A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma.
R. A. Messmann, E. S. Vitetta, D. Headlee, A. M. Senderowicz, W. D. Figg, J. Schindler, D. F. Michiel, S. Creekmore, S. M. Steinberg, D. Kohler, et al. (2000)
Clin. Cancer Res. 6, 1302-1313
   Abstract »    Full Text »
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.
D. B. Axworthy, J. M. Reno, M. D. Hylarides, R. W. Mallett, L. J. Theodore, L. M. Gustavson, F.-M. Su, L. J. Hobson, P. L. Beaumier, and A. R. Fritzberg (2000)
PNAS 97, 1802-1807
   Abstract »    Full Text »    PDF »
Pharmacokinetics and Antitumor Activity of a Bivalent Disulfide-stabilized Fv Immunotoxin with Improved Antigen Binding to erbB2.
T. K. Bera, J. Viner, E. Brinkmann, and I. Pastan (1999)
Cancer Res. 59, 4018-4022
   Abstract »    Full Text »    PDF »
A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma.
A. Engert, V. Diehl, R. Schnell, A. Radszuhn, M.-T. Hatwig, S. Drillich, G. Schon, H. Bohlen, H. Tesch, M.-L. Hansmann, et al. (1997)
Blood 89, 403-410
   Abstract »    Full Text »    PDF »
The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans.
E. Mesri, M Ono, R. Kreitman, M Klagsbrun, and I Pastan (1994)
J. Cell Sci. 107, 2599-2608
   Abstract »    PDF »
Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.
P. Trail, D Willner, S. Lasch, A. Henderson, S Hofstead, A. Casazza, R. Firestone, I Hellstrom, and K. Hellstrom (1993)
Science 261, 212-215
   Abstract »    PDF »
Recombinant toxins for cancer treatment.
I Pastan and D FitzGerald (1991)
Science 254, 1173-1177
   Abstract »    PDF »
Monoclonal antibodies in diagnosis and therapy.
T. Waldmann (1991)
Science 252, 1657-1662
   Abstract »    PDF »
HIV-infected cells are killed by rCD4-ricin A chain.
M. Till, V Ghetie, T Gregory, E. Patzer, J. Porter, J. Uhr, D. Capon, and E. Vitetta (1988)
Science 242, 1166-1168
   Abstract »    PDF »
Escherichia coli secretion of an active chimeric antibody fragment.
M Better, C. Chang, R. Robinson, and A. Horwitz (1988)
Science 240, 1041-1043
   Abstract »    PDF »
Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells.
M. Liu, Nussbaum SR, and H. Eisen (1988)
Science 239, 395-398
   Abstract »    PDF »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)